AM I NEXT? NO LOVE AT MODERNA (08/01/25)

AUGUST 1, 2025 — 500 EMPLOYEES TARGETED

One of the country’s major vaccine makers has announced a 10% reduction in its global workforce.

The reduction will impact approximately 500 employees.

CEO Stéphane Bancel memo…

Dear Team,

Today, I am sharing a difficult decision but necessary step forward: We are reducing the size of our workforce by approximately 10% globally. By the end of the year, we expect to be fewer than 5,000 colleagues strong.

This decision was not made lightly. It impacts teammates and friends who have dedicated themselves to our mission and who have helped build Moderna. I want to express, on behalf of the entire Executive Committee and on behalf of patients you have served, our deepest thanks for everything you have contributed.

Earlier this year, we committed to reducing our annual operating expenses by approximately $1.5 billion by 2027. We’ve made significant progress by scaling down R&D as respiratory trials conclude, renegotiating supplier agreements, and reducing manufacturing costs. Every effort was made to avoid affecting jobs. But today, reshaping our operating structure and aligning our cost structure to the realities of our business are essential to remain focused and financially disciplined, while continuing to invest in our science on the path to 2027.

I know this is a difficult moment for the company. We all feel a range of emotions whenever we have to say goodbye to colleagues.

For those leaving Moderna: We are so grateful for your contributions. You helped shape our culture and advance our mission. You will always be part of our story, and we are here to support you through this transition.

Our mission remains unchanged. With three approved products and the potential for up to eight more approvals in the next three years, the future of Moderna is bright. We are sharpening our focus, becoming leaner, and staying ambitious in oncology, rare diseases and latent viruses.

We will talk more about this at tomorrow’s Town Hall. Please bring your questions.

Thank you for everything you do for patients, for science and for each other.

With gratitude,

Stephane

MARCH 26, 2024 — Original post…

Cambridge, Massachusetts-based Moderna, a pharmaceutical and biotechnology company focusing on mRNA vaccines, has announced a reduction in force.

Responding to lowered demands for COVID-19 therapeutics, the company has laid off an unspecified number of manufacturing and quality-assurance employees in its Burlington, Massachusetts, and Norwood, Massachusetts, facilities. This comes as the company has completed the construction of a new mRNA manufacturing facility in Quebec, Canada.

According to a company spokesperson noting previously announced decisions to reduce COVID-related manufacturing expenditures, the layoffs are occurring in the company's manufacturing unit in response to resizing its COVID production work. We thank these individuals for their contributions to Moderna and to patients worldwide.”

Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. We see good people being laid off through no fault of their own. Just because something bad hasn't happened yet doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. Are you now wondering, Am I Next?

AM I NEXT? NO LOVE AT SANDOZ

Basel, Switzerland-based Sandoz, a generic pharmaceutical company, has announced plans to close its manufacturing facility in Wilson, North Carolina before the end of 2024.

The closure will impact 213 employees.

According to a company spokesperson, "To remain cost-competitive, it is important to use our sites to full production capacity. In the case of the Wilson site, we have been trying for a while to bring in more volume, but despite all our efforts, not enough options have materialized. This was not a surprise to our associates. We've been fully transparent for years about the closing of the plant. We care about our associates, and we've been intent on respecting and supporting them throughout this process."

Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. We see good people being laid off through no fault of their own. Just because something bad hasn't happened yet doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. Are you now wondering, Am I Next?

AM I NEXT? NO LOVE AT LONZA GROUP

Basel, Switzerland-based Lonza Group, a pharmaceutical Contract drug development and manufacturing company, has announced the closure of its 120,000-square-foot Hayward, California manufacturing facility it purchased in 2017.

The closure will impact 218 employees, including positions in management, human resources, engineering and technical services, environment, health and safety, finance, microbiology, manufacturing, science and technology, and quality control. .

According to a company spokesperson, "Lonza is preparing to decommission the mammalian clinical manufacturing facility in Hayward. The phased closure is expected to kick off in the first quarter of 2024 and conclude in the first quarter of 2025. This decision has been reached as CDMO [contract development and manufacturing organization] market demand is focused on combined and integrated clinical-commercial offerings, and the Hayward site provides limited growth opportunities beyond its clinical scope."

Change is coming. There will always be a tomorrow, no matter how much you may try to ignore it. There are no guarantees in life or promises for a bright future. We see good people being laid off through no fault of their own. Just because something bad hasn't happened yet doesn't mean it won't. It can happen to anyone, anytime, anywhere. No one is guaranteed to wake up tomorrow and still have a job by evening. Are you now wondering, Am I Next?